Aviva’s Syndax Pharmaceuticals SNDX Stock Holding History

Aviva’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-60,318	Closed	-$423K	–	754
2018 Q2	$423K	Buy	+60,318	New	+$592K	﹤0.01%	717

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aviva's SNDX Position: Q3 2018 in Review

Aviva sold out of Syndax Pharmaceuticals (SNDX) in Q3 2018, closing a stake of 60,318 shares — an estimated $423K sold.

Aviva first reported a position in SNDX in Q2 2018 and held it in 1 quarter. The position peaked at $423K in Q2 2018. 75 funds tracked by Wall St. Rank hold SNDX as of Q3 2018.

Aviva reported no remaining Syndax Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Aviva sold 60,318 Syndax Pharmaceuticals shares in Q3 2018, an estimated $423K.
Aviva first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Aviva's Syndax Pharmaceuticals position peaked at $423K in Q2 2018.
75 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2018.

Based on Aviva's 13F filing for Q3 2018, filed 13 Nov 2018.